Ken Griffin Supernus Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$25.99 - $33.85 $111,757 - $145,555	-4,300 Reduced 45.26%	5,200 $139,000
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $138,261 - $179,367	-5,100 Reduced 34.93%	9,500 $324,000
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $288,544 - $376,936	12,700 Added 668.42%	14,600 $422,000
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $13,785 - $16,455	-500 Reduced 20.83%	1,900 $52,000
Q2 2023 Aug 14, 2023	BUY	$29.91 - $38.73 $41,874 - $54,221	1,400 Added 140.0%	2,400 $72,000
Q1 2023 May 15, 2023	BUY	$34.93 - $42.03 $27,944 - $33,624	800 Added 400.0%	1,000 $36,000
Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $6,218 - $7,576	200 New	200 $7,000

264

59.4M

47.9K

13.1K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.02B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.